Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04684433
Other study ID # CHUB-Farid
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 14, 2020
Est. completion date March 15, 2021

Study information

Verified date March 2021
Source Brugmann University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The ongoing coronavirus disease 2019 (COVID-19) which started in China, was declared on the 11th of March as a global pandemic 2020 by the World Health Organization (WHO). Governments around the world have introduced differing forms of lock downs since the start of the pandemic demanding citizens to confine to their homes and go out only in necessity to minimize exposure to the virus. The response was observed in the emergency departments and the number of patients who presented for non-Covid issues drastically reduced. Hospitals activated their mass casualty management plans and have reorganized and overstretched their capacity to be able to absorb both the influx of patients with the virus and those with other conditions. Part of that reorganization was reducing the surgical activity. The main focus was shifted to patients who are considered urgent and elective surgery were postponed. Hence only surgical emergencies were maintained. Many did not present to the emergency department for fear to contract the virus and from a sense of national and global solidarity against that pandemic. Whereas these measures are essential to prevent the spread of the virus, it may be hypothesized that for non-Covid issues, including surgical emergencies, patients may present late to the emergency department due to fear of contracting the infection in hospital. This would delay their management and lead to a worsened symptomology on presentation requiring a more complex surgical intervention with an increased complication profile. The investigators present initial data from four major hospitals in Belgium, characterizing surgical emergencies that were managed since the start of the pandemic and discuss the repercussion the pandemic has on management of urgent surgical patients and most likely evolution of surgery after the pandemic.


Recruitment information / eligibility

Status Completed
Enrollment 707
Est. completion date March 15, 2021
Est. primary completion date March 15, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: Patients who had a surgical procedure since the start of the lock down in Belgium due to the COVID19 pandemic (16 of March 2020 to the 12 of April 2020). Exclusion Criteria: None

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Data extraction from medical files
Data extraction from medical files

Locations

Country Name City State
Belgium UZ Brussel Brussel
Belgium CHU Brugmann Brussels
Belgium Erasme Brussels
Belgium St Pierre Brussels

Sponsors (1)

Lead Sponsor Collaborator
Brugmann University Hospital

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Surgery code Type of surgery as defined by the surgery code 5 minutes
Primary Urgency Degree of urgency of the surgery 5 minutes
Primary Type of anesthesia Type of anesthesia 5 minutes
Primary Delay between surgery and first symptoms Delay between surgery and first symptoms 5 minutes
Primary Surgery duration Surgery duration (anesthesia included) 5 minutes
Primary Hospital stay (in days) Hospital stay (in days) 5 minutes
Primary Intensive care unit stay (in days) Intensive care unit stay (in days) 5 minutes
Primary Post-op complications Post-op complications 5 minutes
Primary Covid status before surgery Covid status before surgery (positive=1, negative=0 ) 5 minutes
Primary Covid status post-surgery Covid status post-op (positive=1, negative=0 ) 5 minutes
Primary COVID19 Diagnosis by CT scan COVID19 Diagnosis confirmed by CT scan of the thorax (Yes=1, No=0) 5 minutes
Primary COVID19 Diagnosis by swab test COVID19 Diagnosis by swab test (Yes=1, No=0) 5 minutes
Primary COVID 19 Diagnosis by antibody test COVID 19 Diagnosis by antibody test (Yes=1, No=0) 5 minutes
Primary COVID19 symptoms - dry cough dry cough (Yes=1, No=0) 5 minutes
Primary COVID19 symptoms - fever fever (Yes=1, No=0) 5 minutes
Primary COVID19 symptoms - myalgia myalgia (Yes=1, No=0) 5 minutes
Primary COVID19 symptoms - anosmia anosmia (Yes=1, No=0) 5 minutes
Primary COVID19 symptoms -respiratory distress respiratory distress (Yes=1, No=0) 5 minutes
Primary Treatment for COVID19 - Plaquenil Plaquenil (Yes=1, No=0) 5 minutes
Primary Treatment for COVID19 - Antivirals Antivirals (Yes=1, No=0) 5 minutes
Primary Need for intubation Need for intubation (Yes=1, No=0) 5 minutes
Primary Death Mortality (Yes=1, No=0) 5 minutes
Secondary Age Patient age 5 minutes
Secondary Gender Patient gender 5 minutes
Secondary Ethnicity Patient ethnicity 5 minutes
Secondary BMI Patient Body Mass Index 5 minutes
Secondary Comorbidities Patient comorbidities 5 minutes
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3